{"disease":{"id":"recurrent-fibrolamellar-carcinoma","name":"recurrent fibrolamellar carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06620302","title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"Children's Oncology Group","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}